A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD).
about
Novel and functional norepinephrine transporter protein variants identified in attention-deficit hyperactivity disorderAdolescent impulsivity phenotypes characterized by distinct brain networks.Possible association of norepinephrine transporter -3081(A/T) polymorphism with methylphenidate response in attention deficit hyperactivity disorderA randomized controlled trial investigation of a non-stimulant in attention deficit hyperactivity disorder (ACTION): rationale and design.Conotoxins that confer therapeutic possibilities.Variants of Dopamine Beta Hydroxylase Gene Moderate Atomoxetine Response in Children with Attention-Deficit/Hyperactivity Disorder.Possible effect of norepinephrine transporter polymorphisms on methylphenidate-induced changes in neuropsychological function in attention-deficit hyperactivity disorder.A current update on ADHD pharmacogenomics.Neurobiology of attention deficit/hyperactivity disorder.Toward quality care in ADHD: defining the goals of treatment.ADHD pharmacogenetics across the life cycle: New findings and perspectives.Should we keep on? Looking into pharmacogenomics of ADHD in adulthood from a different perspective.The efficacy of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of clinical research.Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability.Adrenergic neurotransmitter system transporter and receptor genes associated with atomoxetine response in attention-deficit hyperactivity disorder children.A high density linkage disequilibrium mapping in 14 noradrenergic genes: evidence of association between SLC6A2, ADRA1B and ADHD.No association of the norepinephrine transporter gene (SLC6A2) and cognitive and behavioural phenotypes of patients with autism spectrum disorder.No evidence for association between a functional promoter variant of the Norepinephrine Transporter gene SLC6A2 and ADHD in a family-based sample
P2860
Q33571104-5C98AC8B-4D4F-4BBB-8B39-54A7BED56467Q34031695-A63A1C3E-327F-4A96-8CE1-90A72844C4FFQ34221423-EBE9A43E-4429-42FC-9302-874C3CAFBC92Q34743710-47F7A339-8DD7-4147-B329-5B8FC7475644Q36096681-1B295565-E912-42BF-8C0C-B6A5E3B97B41Q36191809-AB064F84-114D-41A8-8E06-241D9E544E8BQ36430286-600CF396-43A9-4C6A-ACC6-0D9E5DAE7919Q37710514-F2AE6490-CF86-4EE7-8100-6131E08AACDCQ37834929-F5949A68-B423-443A-BE52-0518FF4A883AQ38082894-AE053F14-62DF-4A97-B88A-B730F59B2A26Q38209972-5B85DD2A-D843-4CAA-831A-79C309B45A24Q38243174-BCDF7F57-4A94-4F8D-9DBA-BC3F7620A313Q38362252-85D9D867-2B84-4B45-908F-F9DD01DC9349Q38575185-ABCFA217-9C18-40D2-91E1-DD0F58173E20Q43429050-53A59FAB-02F5-4DFB-846C-57A563889D40Q45896638-95A618C3-9B57-430E-A496-787641CAC219Q48900919-2A7EB6B9-61B5-4FF2-8BB8-6169FE30CD59Q58408163-9D1C7AB2-CFFC-4FF4-B1D9-909ECB6AB151
P2860
A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD).
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
A haplotype of the norepinephr ...... hyperactivity disorder (ADHD).
@en
A haplotype of the norepinephrine transporter
@nl
type
label
A haplotype of the norepinephr ...... hyperactivity disorder (ADHD).
@en
A haplotype of the norepinephrine transporter
@nl
prefLabel
A haplotype of the norepinephr ...... hyperactivity disorder (ADHD).
@en
A haplotype of the norepinephrine transporter
@nl
P2093
P2860
P50
P356
P1476
A haplotype of the norepinephr ...... hyperactivity disorder (ADHD).
@en
P2093
Albert J Allen
Angela M Prokop
Anncatherine M Downing
Claudette Boni
Michel Hamon
Sandra L Close
Sandra L Peters
P2860
P2888
P304
P356
10.1038/NPP.2009.39
P407
P577
2009-04-22T00:00:00Z